A5008690554- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- TGF-β signaling in diseases
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Cancer Mechanisms and Therapy
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Immune cells in cancer
- Circular RNAs in diseases
- FOXO transcription factor regulation
- Cardiac Fibrosis and Remodeling
- Cardiovascular Effects of Exercise
- interferon and immune responses
- Drug Transport and Resistance Mechanisms
- MicroRNA in disease regulation
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Protein Tyrosine Phosphatases
- Macrophage Migration Inhibitory Factor
University of the Basque Country
2025
Universidad de Navarra
2011-2024
Navarre Institute of Health Research
2023
Chartered Institute of Management Accountants
2015-2018
Abstract Many antitumor therapies affect rapidly dividing cells. However, tumor proliferation may be driven by cancer stem cells (CSCs), which divide slowly and are relatively resistant to cytotoxic drugs. Thus, many tumors progress because CSCs not sensitive the treatment. In this work, we searched for target genes whose expression is involved in chemoresistance of CSCs. Both these processes could controlled simultaneously cell regulators such as microRNAs (miRNAs). Therefore, colonospheres...
Abstract Background The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipids availability has been appreciated as a mechanism modulate oncogenic potential. Thus, phospholipid transporters play functional role KRAS-driven oncogenesis. Here, we identified systematically studied the transporter PITPNC1 its controlled network LUAD PDAC. Methods...
Abstract Background Inhibitor of DNA binding 1 (Id1) and 3 (Id3) genes have been related with the inhibition cell differentiation, growth promotion tumor metastasis. Recently, Id1 has identified as an independent prognostic factor in patients lung adenocarcinoma, regardless stage. Furthermore, may confer resistance to treatment (both, radiotherapy chemotherapy). Methods We studied, using monoclonal antibodies for immunohistochemistry, Id3 epithelial expression 17 stage III-N2 non-small...
AIM:To investigate the angiogenesis-related protein expression profile characterizing metastatic colorectal cancer (mCRC) with aim of identifying prognostic markers. METHODS:The 44 angiogenesissecreted factors was measured by a novel cytokine antibody array methodology.The study evaluated vascular endothelial growth factor (VEGF) and its soluble receptor (sVEGFR)-1 levels enzyme immunoassay (EIA) in panel 16 CRC cell lines.mRNA VEGF VEGF-A isoforms were quantified quantitative...
Drug combinations are key to circumvent resistance mechanisms compromising response single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators effectors. However, antitumor effect is highly determined by compensatory arising defined cell types tumor subgroups. A potential strategy find drug a larger fraction may capitalize...
Abstract Background The identification of novel therapeutic strategies to overcome resistance the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes effects on Id1 protein, key factor involved oncogenic pathway, and investigates role acquired as well synergistic anticancer effect combined with immunotherapy -mutant LUAD. Methods We evaluated LUAD by Western blot, RNA-seq different syngeneic mouse models. Genetic modulation expression was...
To identify whether circulating levels of angiogenesis-related factors may be predictive bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. Pre-treatment serum 24 cytokines were measured using a multiplex bead assay (MBA) 32 mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 also validated by enzyme-linked immunosorbent (ELISA) at different time points during Higher...
Liver metastases appear in 20–30% of patients diagnosed with non-small cell lung cancer (NSCLC) and represent a poor prognosis feature NSCLC possibly more treatment-resistant condition. Potential clinical outcome differences liver harboring molecular alterations EGFR, KRAS EML4-ALK genes are still to be determined. This study aims evaluate the incidence metastasis single population look for potential correlations between EGFR mutations, infiltration outcomes. A total 236 consecutive stage IV...
Abstract Because of the refractory nature mutant KRAS lung adenocarcinoma (LUAD) to current therapies, identification new molecular targets is essential. Genes with a prognostic role in LUAD have proven be potential for therapeutic development. Here we determine clinical, functional, and mechanistic inhibitor differentiation-1 (Id1) LUAD. Analysis cohorts from TCGA SPORE showed that high expression Id1 was marker poor survival patients harboring mutant, but not wild-type KRAS. Abrogation...
We studied whether thymidylate synthase (TS) genotype has an independent prognostic/predictive impact on a European population of advanced non-small cell lung cancer (NSCLC) patients receiving pemetrexed. Twenty-five treated with pemetrexed-based regimens were included. Genomic DNA was isolated prior to treatment. The variable number tandem repeat (VNTR) polymorphisms, the G > C single nucleotide polymorphisms (SNP) and TS 6-bp insertion/deletion (6/6) in 3′ untranslated region (UTR)...
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from blockade, largely because immunosuppression. New immunotherapy-based combinations are under investigation an attempt to improve outcomes. Id1 (inhibitor differentiation 1) involved In this study, we explored the potential synergistic effect combination inhibition and pharmacological PD-L1 blockade three different syngeneic murine KRAS-mutant lung...
What’s known on the subject? and What does study add? SXR MDR1 are as responsible for chemo radiotherapy resistance in some cancers, like kidney cancer (MDR1). Invasive bladder is an aggressive disease, with different behaviour upon its tumoral stage, also within same therefore molecular markers sought. This shows a new marker, which has shown predictor bad prognosis therefore, allowing us better patient selection therapies. OBJECTIVE • To investigate prognostic value of steroid xenobiotic...
e14057 Background: MicroRNAs (miRNA), small non-coding RNA molecules act as post-transcriptional regulators of gene expression and have shown diagnostic prognostic potential in cancer. We profiled miRNA LARC patients treated with neoadjuvant CRT to assess whether a signature correlated the degree pathological response. Methods: FFPE-derived tumour samples from 85 preoperative (45 Gy plus 5.4 boost, 180-cGy daily fractions concurrent capecitabine) were analyzed for generation IHQ-EGFR protein...
Harnessing the anti-tumor immune system response by targeting program cell death protein (PD-1) and ligand (PD-L1) axis has been a major breakthrough in non-small lung cancer (NSCLC) therapy. Nonetheless, conventional imaging tools cannot accurately assess immunotherapy-treated patients. Using syngeneic mouse model responder to immunotherapy, we aimed demonstrate that [89Zr]-anti-PD-1 immuno-PET is safe feasible modality PD-1/PD-L1 blockade NSCLC.A anti-PD-1 therapy was used. Tumor growth...
Inhibitor of differentiation-1 (Id1) plays a role in cell proliferation, acquisition epithelial to mesenchymal transition (EMT) features and angiogenesis. Id1 was shown be expressed some tumor types, mainly advanced dedifferentiated stages. However, recent studies using validated highly specific monoclonal antibody against have challenged many the results obtained by immunohistochemistry. The goal our work perform thorough analysis expression mouse embryos adult tissues, as well healthy...
<title>Abstract</title> <bold>Background</bold> The identification of novel therapeutic strategies to overcome the intrinsic or acquired resistance trametinib in mutant <italic>KRAS</italic> lung adenocarcinoma (LUAD) is a major challenge. This study analyzes effects <italic>Id1</italic>, key factor involved oncogenic pathway, and investigates <italic>Id1</italic> role acquire synergy with immunotherapy <italic>KRAS</italic>-driven LUAD.<bold>Methods</bold> We evaluated...